SCHEMBL4677444

SCHEMBL4677444

CC[C@H](N)C(=O)NNC(=O)NCc1ccccc1SC

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
ALDH1A1 P00352 5/20 0.39
CHRM2 P08172 1/20 0.39
MAPT P10636 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CTSC P53634 2/20 0.37
KMT2A Q03164 4/20 0.36
GAA P10253 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MEN1 O00255 3/20 0.36
MAPK14 Q16539 1/20 0.36
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
ANPEP P15144 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4680722 1.00 LMNA (0.42) LMNAALDH1A1CHRM2MAPTL3MBTL1
SCHEMBL4677842 0.88 CYP2C9 (0.44) LMNAALDH1A1MAPTL3MBTL1CTSC
SCHEMBL4677566 0.88 CYP2C9 (0.44) LMNAALDH1A1MAPTL3MBTL1CTSC
SCHEMBL4677405 0.82 ALDH1A1 (0.60) ALDH1A1KMT2ANPC1RAB9AMEN1
SCHEMBL4678494 0.82 ALDH1A1 (0.60) ALDH1A1KMT2ANPC1RAB9AMEN1
SCHEMBL4676452 0.82 ANPEP (0.52) LMNAALDH1A1MAPTCTSCKMT2A
SCHEMBL4676430 0.82 ANPEP (0.52) LMNAALDH1A1MAPTCTSCKMT2A
SCHEMBL4677631 0.80 MEN1 (0.53) MAPTKMT2AMEN1ANPEP
SCHEMBL4680712 0.80 TPH1 (0.46) ALDH1A1MAPTCTSCKMT2A
SCHEMBL4677836 0.80 TPH1 (0.46) ALDH1A1MAPTCTSCKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633702-B1 PROTEASE INHIBITORS PROZYMEX AS (DK) 2008-07-02 EP claimed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US claimed
EP-1633702-A1 PROTEASE INHIBITORS Prozymex A/S (DK) 2006-03-15 EP claimed
WO-2004106289-A1 PROTEASE INHIBITORS PROZYMEX A/S (DK) 2004-12-09 WO claimed
EP-1975153-A2 Protease inhibitors Prozymex A/S (DK) 2008-10-01 EP disclosed
EP-1975153-A2 Protease inhibitors Prozymex A/S (DK) 2008-10-01 EP disclosed
EP-1633702-B1 PROTEASE INHIBITORS PROZYMEX AS (DK) 2008-07-02 EP disclosed
EP-1633702-B1 PROTEASE INHIBITORS PROZYMEX AS (DK) 2008-07-02 EP disclosed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US disclosed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US disclosed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US disclosed
EP-1633702-A1 PROTEASE INHIBITORS Prozymex A/S (DK) 2006-03-15 EP disclosed
WO-2004106289-A1 PROTEASE INHIBITORS PROZYMEX A/S (DK) 2004-12-09 WO disclosed
WO-2004106289-A1 PROTEASE INHIBITORS PROZYMEX A/S (DK) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155803-A1 Protease inhibitors DPP7, DPP9, DPP3 LMNA 2281/4885ALDH1A1 2713/4885CHRM2 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.